Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Weekly digests, breaking news, and analyses from the world of psychedelic research
Not everyone should take psychedelics. Learn about critical contraindications including psychotic disorders, cardiovascular conditions, dangerous drug interactions, and proper screening.
The 5-HT2A serotonin receptor is the molecular key to all classic psychedelic effects. Learn how this receptor drives consciousness changes, neuroplasticity, and therapeutic outcomes.
Psychedelic integration therapy is the key to lasting therapeutic outcomes. Learn why the process after the trip matters more than the experience itself.
Ibogaine shows unique potential to interrupt opioid addiction with a single treatment, but carries serious cardiac risks. Explore the research, safety concerns, and safer analogs.
Switzerland's BAG allows psychedelic therapy through exceptional permits. Learn about the regulatory framework, available substances, research institutions, and access pathways.
Psychedelics dramatically alter brain function by reducing default mode network activity and increasing neural connectivity. Learn how these changes drive therapeutic effects.
Microdosing psilocybin is popular but controversial. Explore the scientific evidence, potential benefits, placebo effects, and health risks of sub-perceptual psychedelic dosing.
Ketamine infusions offer rapid relief for treatment-resistant depression. Learn about IV protocols, esketamine (Spravato), mechanisms of action, and clinical evidence.
MDMA-assisted therapy shows unprecedented efficacy for PTSD treatment. Explore Phase 3 trial results, brain mechanisms, safety data, and regulatory developments.
Psilocybin-assisted therapy is showing remarkable results for treatment-resistant depression. Learn what the latest clinical trials reveal about mechanisms, efficacy, and risks.
Australia becomes the first country to approve MDMA for PTSD and psilocybin for treatment-resistant depression, setting a global precedent for psychedelic medicine regulation.
Our first weekly digest: 42 new studies indexed, key findings in psilocybin depression research, MDMA Phase 3 updates, and ketamine dosing optimization from Yale.